XNASGNLX
Market cap79mUSD
Jan 15, Last price
2.29USD
1D
-4.18%
1Q
-18.51%
IPO
-61.90%
Name
Genelux Corp
Chart & Performance
P/E
—
P/S
465.25
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
170k
-98.46%
Net income
-28m
L+443.44%
CFO
-20m
L+467.77%
Profile
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary, modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small-cell lung cancer. The company is also developing V2ACT Immunotherapy for the treatment of pancreatic cancer; and V-VET1 to treat hematologic and solid cancer. The company was incorporated in 2001 and is headquartered in Westlake Village, California.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | |
| Income | |||||
Revenues | 170 -98.46% | 11,068 | |||
Cost of revenue | 25,353 | 15,049 | |||
Unusual Expense (Income) | |||||
NOPBT | (25,183) | (3,981) | |||
NOPBT Margin | |||||
Operating Taxes | 1,100 | ||||
Tax Rate | |||||
NOPAT | (25,183) | (5,081) | |||
Net income | (28,297) 443.44% | (5,207) -70.74% | |||
Dividends | |||||
Dividend yield | |||||
Proceeds from repurchase of equity | 39,645 | 120 | |||
BB yield | -11.58% | ||||
| Debt | |||||
Debt current | 1,306 | 16,665 | |||
Long-term debt | 4,385 | 11,118 | |||
Deferred revenue | |||||
Other long-term liabilities | |||||
Net debt | (17,500) | 27,386 | |||
| Cash flow | |||||
Cash from operating activities | (20,275) | (3,571) | |||
CAPEX | (1,025) | (49) | |||
Cash from investing activities | (14,724) | (49) | |||
Cash from financing activities | 44,020 | (478) | |||
FCF | (39,871) | (1,883) | |||
| Balance | |||||
Cash | 23,191 | 397 | |||
Long term investments | |||||
Excess cash | 23,182 | ||||
Stockholders' equity | (221,483) | (189,751) | |||
Invested Capital | 244,128 | 180,321 | |||
ROIC | |||||
ROCE | 42.22% | ||||
| EV | |||||
Common stock shares outstanding | 24,429 | 24,553 | |||
Price | 14.01 | ||||
Market cap | 342,254 | ||||
EV | 324,754 | ||||
EBITDA | (24,165) | (3,013) | |||
EV/EBITDA | |||||
Interest | 3,974 | 1,408 | |||
Interest/NOPBT | |||||